Peptides MetabolicMuscle Building Preclinical (animal) data

SLU-PP-332

SLU-PP332 · ERR agonist

4.8 hours

Half-life

5–30 mg

Typical dose

4–8 weeks (reported, anecdotal)

Cycle length

Estrogen-related receptor agonism ("exercise mimetic") researched for metabolic and endurance effects.

Key takeaways

Small-molecule pan-ERR agonist ("exercise mimetic"); despite the listing, it isn't a peptide.
All evidence is mouse and cell work; zero human trials, zero approved use.
Plotter values are modeled estimates, not measured pharmacokinetics.
Community dosing (5–30 mg oral) is extrapolated from animal studies and purely anecdotal.

🚧 Expanded guide coming soon. This compound has PK data and a source — a full overview, mechanism, and dosing guide is pending editorial review.

Reported dosing protocols

Protocols reported in research literature and clinic/community use — informational context, not a dosing recommendation.

Use case	Dose	Route	Frequency	Duration
Metabolic / endurance (community)	5–30 mg	Oral	Once daily	4–8 weeks reported

Pharmacokinetic summary

Model tier: Simple (t½ + F, Tmax estimated)
Half-life: 4.8 hours
Bioavailability: 50%
Typical dose: 5–30 mg

Frequently asked questions

Is SLU-PP-332 a peptide?

No. It's a synthetic small molecule sold alongside research peptides, which is why it's listed here. It agonizes estrogen-related receptors (ERRs), which despite the name aren't activated by estrogen.

Does SLU-PP-332 replace exercise?

There's no human evidence at all. Mouse studies show exercise-like metabolic changes, but animal exercise mimetics have repeatedly failed to translate, and nothing about human safety or efficacy is known.

Is SLU-PP-332 detectable in drug tests?

Anti-doping labs have published in-vitro metabolism work on SLU-PP-332 for detection purposes, and as an unapproved substance it falls under WADA's prohibited list. Tested athletes should treat it as banned.

References

Estimated (preclinical) — ERRα/β/γ agonist ("exercise mimetic"); human PK not established.
Billon et al., ACS Chem Biol 2023 — ERR agonist induces an aerobic exercise response — Original mouse study: ERRα-dependent exercise response and enhanced exercise capacity.
Billon et al., J Pharmacol Exp Ther 2024 — ERR agonist alleviates metabolic syndrome — Mouse study: increased energy expenditure and fatty-acid oxidation in metabolic-syndrome models.
Avliyakulov & Sobolevsky, Drug Test Anal 2026 — SLU-PP-332 metabolites for doping control — In-vitro metabolite identification for anti-doping detection.

Comments

Loading comments…